Journal of Aerosol Medicine and Pulmonary Drug Delivery

Scope & Guideline

Advancing aerosol science for better respiratory health.

Introduction

Welcome to your portal for understanding Journal of Aerosol Medicine and Pulmonary Drug Delivery, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1941-2711
PublisherMARY ANN LIEBERT, INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2008 to 2024
AbbreviationJ AEROSOL MED PULM D / J. Aerosol Med. Pulm. Drug Deliv.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801

Aims and Scopes

The Journal of Aerosol Medicine and Pulmonary Drug Delivery focuses on advancing the science and application of aerosol-based therapies, particularly in the domain of respiratory medicine. The journal encompasses a multidisciplinary approach that includes pharmacology, engineering, and clinical studies to enhance drug delivery systems and their efficacy in treating respiratory conditions.
  1. Aerosol Drug Delivery Systems:
    Research in this area includes the development and optimization of various aerosol drug delivery devices, such as metered-dose inhalers (MDIs), nebulizers, and dry powder inhalers (DPIs). Studies often focus on how device characteristics influence drug delivery efficiency and patient outcomes.
  2. Pharmacokinetics and Pharmacodynamics of Inhaled Medications:
    This includes investigations into the absorption, distribution, metabolism, and excretion of inhaled drugs. Understanding the pharmacokinetic profiles of medications delivered via aerosols is crucial for optimizing dosing regimens and therapeutic efficacy.
  3. Innovative Formulation Development:
    Research on novel formulations, including liposomal, nanoparticle, and polymer-based systems, aims to enhance the stability, solubility, and delivery of active pharmaceutical ingredients (APIs) through inhalation.
  4. Clinical Outcomes and Patient-Centric Studies:
    The journal emphasizes studies that evaluate the clinical effectiveness of aerosol therapies in real-world settings, focusing on patient adherence, usability of inhalation devices, and overall treatment outcomes.
  5. In Vitro and In Vivo Models:
    A significant portion of research employs advanced in vitro and in vivo models to simulate respiratory conditions and assess aerosol deposition, drug efficacy, and safety profiles.
The Journal of Aerosol Medicine and Pulmonary Drug Delivery has witnessed a dynamic evolution in its thematic focus, reflecting emerging trends in aerosol therapy and respiratory medicine. Recent publications indicate a strong inclination towards innovative technologies and novel therapeutic approaches.
  1. Nanoparticle and Nanotechnology Applications:
    Increasing interest in the use of nanoparticles for drug delivery, particularly for targeting lung diseases such as tuberculosis and cancer, highlights a shift toward more sophisticated and effective inhalation therapies.
  2. Personalized Medicine Approaches:
    Research into personalized inhalation therapies that consider individual patient characteristics and preferences is gaining traction, indicating a move towards more tailored therapeutic strategies.
  3. Impact of E-Cigarettes and Vaping on Respiratory Health:
    With the rise in vaping, studies examining the effects of e-cigarette aerosols on respiratory function and health outcomes are becoming more prevalent, reflecting public health concerns.
  4. Advanced In Vitro Models for Drug Testing:
    The development of sophisticated in vitro systems that mimic human respiratory conditions for drug testing is emerging as a critical area of research, enhancing the predictive value of preclinical studies.
  5. Sustainability in Aerosol Delivery Devices:
    There is a growing focus on developing environmentally sustainable inhaler technologies, particularly in response to regulatory pressures and public demand for greener pharmaceutical practices.

Declining or Waning

While the journal continues to explore a broad range of topics related to aerosol medicine, certain themes appear to be declining in prominence over recent years. These waning scopes may reflect shifts in research focus or advancements in technology that render previous areas less critical.
  1. Traditional Nebulization Techniques:
    Research on conventional nebulizer systems appears to be declining as newer technologies, such as vibrating mesh nebulizers and soft mist inhalers, gain popularity for their efficiency and patient convenience.
  2. Non-Inhalation Drug Delivery Methods:
    There is a noticeable decrease in studies focusing on non-inhalation methods of drug delivery within the context of aerosol medicine, as the field shifts towards optimizing inhaled therapies specifically.
  3. Basic Aerosol Science without Clinical Application:
    While foundational aerosol science remains relevant, there seems to be a waning interest in purely theoretical studies that do not directly contribute to clinical applications or improvements in patient care.
  4. Pharmacokinetics of Non-Respiratory Drugs:
    Research focused on the pharmacokinetics of drugs not intended for respiratory diseases has diminished, as the journal's emphasis shifts towards inhaled therapies specifically tailored for respiratory conditions.

Similar Journals

INDIAN JOURNAL OF PHARMACOLOGY

Exploring the frontiers of pharmacology since 1978.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0253-7613Frequency: 6 issues/year

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY

Transforming Ideas into Effective Therapeutics.
Publisher: TAYLOR & FRANCIS LTDISSN: 1083-7450Frequency: 6 issues/year

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY is a premier journal published by Taylor & Francis Ltd that focuses on the latest advancements and innovations in the field of pharmaceutical science. Established in 1996, this journal has evolved to encompass a wide array of interdisciplinary studies relevant to drug development, formulation technology, and delivery systems, serving as a platform for researchers and professionals to share groundbreaking findings. With an impressive impact factor and ranked in both Q2 in Pharmaceutical Science and Q3 in Medicine (miscellaneous), it positions itself among the top-tier journals in pharmacology and toxicology. The journal's insights are critical for scholars and practitioners aiming to enhance therapeutic efficacy and safety. Access options for the content remain traditional, thus supporting a comprehensive approach to scientific literature. Throughout its converged years up to 2024, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY continues to play a vital role in shaping pharmaceutical education and practice.

PHARMACEUTICAL RESEARCH

Leading the charge in pharmaceutical science and drug development.
Publisher: SPRINGER/PLENUM PUBLISHERSISSN: 0724-8741Frequency: 12 issues/year

PHARMACEUTICAL RESEARCH, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the ever-evolving field of pharmaceutical sciences. With an ISSN of 0724-8741 and an E-ISSN of 1573-904X, this journal has established itself as a critical hub for disseminating innovative research from 1984 to 2024. The journal holds impressive rankings in prominent categories, including Q2 in Biotechnology and Q2 in Pharmaceutical Science, reflecting its robust impact on the global scientific community. The journal aims to provide researchers, professionals, and students with high-quality articles that contribute significantly to the advancement of drug development and medicinal applications. Although it does not currently offer Open Access options, its rigorous peer-review process ensures that only the highest caliber research is published, making it a valuable resource for those seeking to stay at the forefront of pharmaceutical innovation.

Pakistan Journal of Pharmaceutical Sciences

Exploring the forefront of pharmaceutical sciences since 1995.
Publisher: UNIV KARACHIISSN: 1011-601XFrequency: 4 issues/year

Pakistan Journal of Pharmaceutical Sciences, published by the University of Karachi, serves as a vital platform for advancing research in the field of pharmaceutical sciences. With a strong commitment to disseminating innovative findings and critical studies since its inception in 1995, the journal focuses on a wide array of topics including pharmacology, toxicology, and pharmaceutics. With an ISSN of 1011-601X, it holds a reputable position within the academic community, reflecting its Q3 category ranking in Pharmaceutical Science as of 2023. While the journal is currently not designated as Open Access, it remains accessible through institutional subscriptions, ensuring that both emerging and established researchers can contribute to and benefit from its scholarly content. This publication not only promotes scientific dialogue but also aims to bridge the gap between academia and industry, appealing to a diverse audience of researchers, professionals, and students seeking to stay informed about the latest advancements and trends in pharmaceutical research.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Exploring therapeutic frontiers for eye diseases.
Publisher: MARY ANN LIEBERT, INCISSN: 1080-7683Frequency: 10 issues/year

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.

Frontiers in Pharmacology

Empowering researchers with cutting-edge insights in pharmacology.
Publisher: FRONTIERS MEDIA SAISSN: Frequency: 1 issue/year

Frontiers in Pharmacology, published by FRONTIERS MEDIA SA, stands as a leading open-access journal dedicated to advancing the field of pharmacology since its inception in 2010. With its ISSN 1663-9812, the journal is based in Switzerland and maintains a vital role in disseminating innovative research findings that span various disciplines within pharmacology, including pharmacokinetics, toxicology, and pharmacogenetics. In 2023, Frontiers in Pharmacology has achieved an impressive standing within the scientific community, being ranked in the Q1 category for both general and medical pharmacology, highlighting its critical contribution to the field with a Scopus ranking of #41 out of 272 in medical pharmacology and #76 out of 313 in pharmacology, toxicology, and pharmaceutics, placing it in the 75th and 85th percentiles, respectively. Researchers and practitioners benefit from its open-access model, which ensures widespread accessibility to groundbreaking research, fostering collaboration and innovation across the pharmaceutical sciences. With its commitment to excellence, Frontiers in Pharmacology serves as an essential resource for those looking to explore and contribute to the latest advancements in pharmacological research.

Journal of Reports in Pharmaceutical Sciences

Bridging Research and Practice in Pharmaceutical Sciences.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

European Journal of Pharmacology

Fostering interdisciplinary collaboration in the realm of pharmacology.
Publisher: ELSEVIERISSN: 0014-2999Frequency: 24 issues/year

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.

Drug Design Development and Therapy

Empowering Drug Discovery Through Open Access Research
Publisher: DOVE MEDICAL PRESS LTDISSN: 1177-8881Frequency: 1 issue/year

Drug Design Development and Therapy is a premier open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of drug discovery, pharmaceutical science, and pharmacology. With an impressive Q1 ranking in its categories as of 2023, this journal is recognized for its significant contributions to the understanding of drug design and therapeutic innovations, making it an invaluable resource for researchers, professionals, and students alike. Established in 2007 and committed to open-access since 2008, the journal provides an inclusive platform for disseminating high-quality research from around the globe. With a robust impact factor and remarkable Scopus rankings, including a 24th place in Pharmaceutical Science and a 48th place in Pharmacology, it reflects a strong percentile performance, ensuring that published articles reach and impact a wide audience. By fostering the exchange of cutting-edge information on drug development and delivery systems, Drug Design Development and Therapy continues to play a crucial role in the ongoing battle against disease, promoting innovative approaches to therapeutic solutions and enhancing patient care.

TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH

Connecting scholars to tackle health challenges in the tropics.
Publisher: PHARMACOTHERAPY GROUPISSN: 1596-5996Frequency: 2 issues/year

Tropical Journal of Pharmaceutical Research is an esteemed open-access platform dedicated to advancing the field of pharmaceutical sciences, published by the Pharmacotherapy Group in Nigeria. With an ISSN of 1596-5996 and open access established since 2002, this journal serves as a critical resource for researchers, professionals, and students seeking to disseminate and access high-quality research in both pharmaceutical science and pharmacology. Despite its ranking in the third quartile (Q3) for Pharmaceutical Science and the fourth quartile (Q4) in Pharmacology as of 2023, the journal continues to stand out with its commitment to fostering significant dialogue and innovation in the scientific community. Anchored at the University of Benin, Faculty of Pharmacy, the journal invites contributions that explore novel pharmaceutical research, clinical applications, and drug development, playing a vital role in addressing health challenges that are particularly relevant to tropical regions. Researchers can look forward to publishing their findings in a journal that not only promotes the sharing of knowledge but also enhances the scientific discourse within a rapidly evolving field.